


=> d que

L3

STR



NODE ATTRIBUTES:

CONNECT IS X2 RC AT 2  
 CONNECT IS E3 RC AT 3  
 CONNECT IS E3 RC AT 4  
 CONNECT IS E3 RC AT 5  
 CONNECT IS E3 RC AT 6  
 CONNECT IS E3 RC AT 7  
 CONNECT IS E2 RC AT 8  
 CONNECT IS E3 RC AT 9  
 CONNECT IS E2 RC AT 10  
 CONNECT IS E3 RC AT 11  
 CONNECT IS E1 RC AT 20  
 CONNECT IS E1 RC AT 21  
 CONNECT IS E1 RC AT 22  
 CONNECT IS E1 RC AT 23  
 CONNECT IS E2 RC AT 25  
 CONNECT IS E1 RC AT 26  
 DEFAULT MLEVEL IS ATOM  
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RSPEC 13  
 NUMBER OF NODES IS 24

STEREO ATTRIBUTES: NONE

L4 125 SEA FILE=REGISTRY SSS FUL L3  
 L5 7 SEA FILE=HCAPLUS ABB=ON PLU=ON L4

=> d ibib abs hitstr 15 1-7

L5 ANSWER 1 OF 7 HCAPLUS COPYRIGHT 2003 ACS  
 ACCESSION NUMBER: 2002:410373 HCAPLUS  
 DOCUMENT NUMBER: 137:137428  
 TITLE: Synthesis and anti-Helicobacter pylori activity of  
 pyloricidin derivatives: II. The combination of amino  
 acid residues in the dipeptidic moiety and its effect  
 on the anti-Helicobacter pylori activity  
 AUTHOR(S): Hasuoka, Atsushi; Nishikimi, Yuji; Nakayama, Yutaka;

May 5, 2003

## CORPORATE SOURCE:

Kamiyama, Keiji; Nakao, Masafumi; Miyagawa,  
 Ken-Ichiro; Nishimura, Osamu; Fujino, Masahiko  
 Medicinal Chemistry Research Laboratories I,  
 Pharmaceutical Research Division, Takeda Chemical  
 Industries, Ltd., Osaka, 532-8686, Japan  
*Journal of Antibiotics* (2002), 55(5), 499-507

## SOURCE:

CODEN: JANTAJ; ISSN: 0021-8820  
 Japan Antibiotics Research Association  
 Journal

## PUBLISHER:

DOCUMENT TYPE:  
LANGUAGE:

English

**AB** The novel natural antibiotics pyloricidin A, B and C, consisting of a common (2S,3R,4R,5S)-5-amino-2,3,4,6-tetrahydroxyhexanoyl-.beta.-D-phenylalanine moiety and a terminal peptidic moiety (pyloricidin A: L-valine-L-valine-L-leucine; pyloricidin B: L-valine-L-leucine; pyloricidin C: L-leucine), exhibit potent and highly selective anti-Helicobacter pylori activity. In order to develop more potent compds. and to investigate structure activity relationships for the peptidic moiety with regard to the combination of amino acids, a series of derivs. with various dipeptidic moieties were prep'd. and evaluated for their anti-H. pylori activity. The combination of the two amino acids in the moiety was found to have a significant effect on the activity; the compd. with Nva-Abu showed excellent anti-H. pylori activity with an MIC value of 0.013 .mu.g/mL against H. pylori TN2. In addn., this compd. was found to show 60% clearance of H. pylori from infected Mongolian gerbils upon repetitive oral administration (10 mg/kg, b. i. d. for 7 days).

IT 219813-04-4 219813-06-6 219813-20-4

219813-31-7 219813-39-5 219813-68-0

219813-69-1 219813-70-4 219823-29-7,

Pyloricidin B 219823-30-0, Pyloricidin C 435342-33-9


435342-40-8 435342-43-1

**RL:** BSU (Biological study, unclassified); BIOL (Biological study)  
 (synthesis and anti-Helicobacter pylori activity of pyloricidin  
 derivs.)

RN 219813-04-4 HCPLUS

CN .beta.-Alanine, L-norvalyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)-  
 (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 219813-06-6 HCPLUS

CN .beta.-Alanine, L-norvalyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)-  
 (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).


May 5, 2003



RN 219813-20-4 HCPLUS

CN .beta.-Alanine, L-methionyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 219813-31-7 HCPLUS

CN .beta.-Alanine, L-asparaginyl-L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 219813-39-5 HCPLUS

CN .beta.-Alanine, L-isoleucyl-L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 219813-68-0 HCPLUS

CN .beta.-Alanine, L-methionyl-L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 219813-69-1 HCPLUS

CN .beta.-Alanine, S-methyl-L-cysteinyl-L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 219813-70-4 HCPLUS

CN .beta.-Alanine, 4,5-didehydro-L-norvalyl-L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).


May 5, 2003



RN 219823-29-7 HCPLUS

CN .beta.-Alanine, L-valyl-L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-,  
(3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 219823-30-0 HCPLUS

CN .beta.-Alanine, L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 435342-33-9 HCPLUS

CN .beta.-Alanine, L-norvalyl-L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-,  
(3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 435342-40-8 HCAPLUS

CN .beta.-Alanine, L-glutamyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-,  
(3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 435342-43-1 HCAPLUS

CN Benzenepropanoic acid, .beta.-[[5-[(2S)-2-amino-1-oxobutyl]amino]-5-deoxy-L-galactonoyl]amino]-, (.beta.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




IT 219813-22-6

RL: BSU (Biological study, unclassified); RCT (Reactant); BIOL (Biological study); RACT (Reactant or reagent)  
(synthesis and anti-Helicobacter pylori activity of pyloricidin derivs.)

RN 219813-22-6 HCAPLUS

CN Benzenepropanoic acid, .beta.-[[5-[(2S)-2-amino-1-oxo-4-pentenyl]amino]-5-deoxy-L-galactonoyl]amino]-, (.beta.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




IT 219813-75-9P 219813-76-0P 219813-77-1P  
282549-81-9P 444718-52-9P 444718-53-0P  
444718-54-1P 444718-55-2P 444718-56-3P  
444718-57-4P 444718-58-5P

RL: BSU (Biological study, unclassified); SPN (Synthetic preparation);  
BIOL (Biological study); PREP (Preparation)  
(synthesis and anti-Helicobacter pylori activity of pyloricidin  
derivs.)

RN 219813-75-9 HCPLUS

CN .beta.-Alanine, L-norvalyl-4,5-didehydro-L-norvalyl-5-amino-5-deoxy-L-  
galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 219813-76-0 HCPLUS

CN .beta.-Alanine, L-isoleucyl-4,5-didehydro-L-norvalyl-5-amino-5-deoxy-L-  
galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 219813-77-1 HCPLUS

CN .beta.-Alanine, L-methionyl-4,5-didehydro-L-norvalyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 282549-81-9 HCPLUS

CN .beta.-Alanine, L-norvalyl-(2S)-2-aminobutanoyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 444718-52-9 HCPLUS

CN .beta.-Alanine, 4,5-didehydro-L-norvalyl-4,5-didehydro-L-norvalyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 444718-53-0 HCPLUS

CN .beta.-Alanine, L-asparaginyl-4,5-didehydro-L-norvalyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 444718-54-1 HCPLUS

CN .beta.-Alanine, S-methyl-L-cysteinyl-4,5-didehydro-L-norvalyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 444718-55-2 HCPLUS

CN .beta.-Alanine, L-norvalyl-L-alanyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-

, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 444718-56-3 HCAPLUS

CN .beta.-Alanine, L-norvalyl-L-norvalyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 444718-57-4 HCAPLUS

CN .beta.-Alanine, L-norvalyl-L-glutaminyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 444718-58-5 HCAPLUS

CN .beta.-Alanine, L-norvalyl-L-methionyl-5-amino-5-deoxy-L-galactonoyl-3-

phenyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 219812-79-0

RL: RCT (Reactant); RACT (Reactant or reagent)  
(synthesis and anti-Helicobacter pylori activity of pyloricidin derivs.)

RN 219812-79-0 HCPLUS

CN Benzenepropanoic acid, .beta.-[(5-amino-5-deoxy-L-galactonoyl)amino]-, (.beta.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

16

THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 7 HCPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:262140 HCPLUS

DOCUMENT NUMBER: 137:30442

TITLE: Synthesis and anti-Helicobacter pylori activity of pyloricidin derivatives: I. Structure-activity relationships on the terminal peptidic moiety

AUTHOR(S): Hasuoka, Atsushi; Nishikimi, Yuji; Nakayama, Yutaka; Kamiyama, Keiji; Nakao, Masafumi; Miyagawa, Ken-Ichiro; Nishimura, Osamu; Fujino, Masahiko

CORPORATE SOURCE: Medicinal Chemistry Research Laboratories I, Pharmaceutical Research Division, Takeda Chemical Industries, Ltd., Osaka, 532-8686, Japan

SOURCE: Journal of Antibiotics (2002), 55(3), 322-336



CODEN: JANTAJ ISSN: 0021-8820

PUBLISHER: Japan Antibiotics Research Association

DOCUMENT TYPE: Journal

LANGUAGE: English

GI



AB The novel natural antibiotics pyloricidin A, B (I) and C (II) possess potent and highly selective antibacterial activity against *Helicobacter pylori*. In order to investigate the structure-activity relationships for the terminal peptidic moiety, a series of I and II derivs., bearing various amino acids in the moiety, were prep'd. and evaluated for their anti-*H. pylori* activity. The derivs. bearing .alpha.-D-, .beta.- and .gamma.-amino acids or peptidemimetics showed drastically decreased activity. On the other hand, the derivs. with .alpha.-L-amino acids were found to maintain the activity. Among the derivs. prep'd. in this work, the allylglycine deriv. III showed the most potent anti-*H. pylori* activity, with an MIC value of less than 0.006 .mu.g/mL against *H. pylori* NCTC11637, which is 60-fold greater than the activity of the lead compd. II. pyloricidin B and pyloricidin C.


IT 219812-79-0

RL: RCT (Reactant); RACT (Reactant or reagent)  
(in synthesis of pyloricidin derivs. modified in the terminal peptidic moiety)

RN 219812-79-0 HCPLUS

CN Benzene propanoic acid, .beta.-[(5-amino-5-deoxy-L-galactonoyl)amino]-, (.beta.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 219823-29-7, Pyloricidin B 219823-30-0, Pyloricidin C

RL: PAC (Pharmacological activity); PRP (Properties); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)  
(synthesis and structure-anti-*Helicobacter pylori* activity relationships of the terminal peptidic moiety of pyloricidin derivs.)

RN 219823-29-7 HCPLUS

CN .beta.-Alanine, L-valyl-L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 219823-30-0 HCPLUS

CN .beta.-Alanine, L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 219812-97-2P 219813-02-2P 219813-04-4P

219813-05-5P 219813-06-6P 219813-08-8P

219813-10-2P 219813-12-4P 219813-15-7P

219813-19-1P 219813-20-4P 219813-21-5P

219813-22-6P 219813-23-7P 219813-25-9P

219813-28-2P 219813-29-3P 219813-30-6P

219813-31-7P 219813-32-8P 219813-37-3P

219813-38-4P 219813-39-5P 219813-41-9P

219813-43-1P 219813-48-6P 219813-53-3P

219813-55-5P 219813-58-8P 219813-68-0P

219813-69-1P 219813-70-4P 219813-73-7P

219813-74-8P 435342-28-2P 435342-29-3P

435342-30-6P 435342-31-7P 435342-32-8P

435342-33-9P 435342-34-0P 435342-35-1P

435342-36-2P 435342-37-3P 435342-38-4P

435342-40-8P 435342-41-9P 435342-42-0P

435342-43-1P 435342-44-2P 435342-45-3P

435342-46-4P 435342-47-5P


RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(synthesis and structure-anti-Helicobacter pylori activity  
relationships of the terminal peptidic moiety of pyloricidin derivs.)

RN 219812-97-2 HCPLUS

CN .beta.-Alanine, O-methyl-L-seryl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-,  
(3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 219813-02-2 HCPLUS

CN .beta.-Alanine, L-isoleucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 219813-04-4 HCPLUS

CN .beta.-Alanine, L-alanyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 219813-05-5 HCPLUS

CN .beta.-Alanine, L-valyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 219813-06-6 HCAPLUS

CN .beta.-Alanine, L-norvalyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 219813-08-8 HCAPLUS

CN .beta.-Alanine, L-phenylalanyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 219813-10-2 HCAPLUS

CN .beta.-Alanine, L-prolyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 219813-12-4 HCAPLUS

CN .beta.-Alanine, 5,5,5-trifluoro-L-norvalyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 219813-15-7 HCAPLUS

CN .beta.-Alanine, 5-fluoro-L-norvalyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 219813-19-1 HCAPLUS

CN .beta.-Alanine, 3-cyano-L-alanyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 219813-20-4 HCPLUS

CN .beta.-Alanine, L-methionyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 219813-21-5 HCPLUS

CN .beta.-Alanine, S-methyl-L-cysteinyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 219813-22-6 HCPLUS

CN Benzenepropanoic acid, .beta.-[[5-[(2S)-2-amino-1-oxo-4-pentenyl]amino]-5-deoxy-L-galactonoyl]amino]-, (.beta.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 219813-23-7 HCPLUS

CN .beta.-Alanine, L-alanyl-L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-,  
(3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 219813-25-9 HCPLUS

CN .beta.-Alanine, L-phenylalanyl-L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 219813-28-2 HCPLUS

CN .beta.-Alanine, L.-alpha.-glutamyl-L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 219813-29-3 HCPLUS

CN .beta.-Alanine, N-(4-amino-1-oxobutyl)-L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 219813-30-6 HCPLUS

CN .beta.-Alanine, L-ornithyl-L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 219813-31-7 HCPLUS

CN .beta.-Alanine, L-asparaginyl-L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 219813-32-8 HCAPLUS

CN .beta.-Alanine, L-glutaminyl-L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 219813-37-3 HCAPLUS

CN .beta.-Alanine, 5,5,5-trifluoro-L-norvalyl-L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 219813-38-4 HCAPLUS

CN .beta.-Alanine, L-leucyl-L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 219813-39-5 HCAPLUS

CN .beta.-Alanine, L-isoleucyl-L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 219813-41-9 HCAPLUS

CN .beta.-Alanine, O-methyl-L-seryl-L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 219813-43-1 HCAPLUS

CN .beta.-Alanine, N-methyl-L-valyl-L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 219813-48-6 HCAPLUS

CN .beta.-Alanine, 3-cyano-L-alanyl-L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


### Absolute stereochemistry. Rotation (-).



RN 219813-53-3 HCAPLUS

CN .beta.-Alanine, glycyl-L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-,  
(3S)- (9CI) (CA INDEX NAME)


### Absolute stereochemistry. Rotation (-).



RN 219813-55-5 HCAPLUS

CN .beta.-Alanine, L-prolyl-L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-,  
(3S)- (9CI) (CA INDEX NAME)


### Absolute stereochemistry. Rotation (-).



RN 219813-58-8 HCPLUS

CN .beta.-Alanine, L-seryl-L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-,  
(3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 219813-68-0 HCPLUS

CN .beta.-Alanine, L-methionyl-L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 219813-69-1 HCPLUS

CN .beta.-Alanine, S-methyl-L-cysteinyl-L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 219813-70-4 HCAPLUS

CN .beta.-Alanine, 4,5-didehydro-L-norvalyl-L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 219813-73-7 HCAPLUS

CN .beta.-Alanine, L-valyl-N-methyl-L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 219813-74-8 HCAPLUS

CN .beta.-Alanine, N-[(2S)-2-amino-3-methylbutyl]-L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 435342-28-2 HCPLUS

CN .beta.-Alanine, D-alanyl-L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-,  
(3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 435342-29-3 HCPLUS

CN .beta.-Alanine, D-valyl-L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-,  
(3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 435342-30-6 HCPLUS

CN .beta.-Alanine, .beta.-alanyl-L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-,  
(3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 435342-31-7 HCAPLUS

CN .beta.-Alanine, L-lysyl-L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-,  
(3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 435342-32-8 HCAPLUS

CN .beta.-Alanine, (2S)-2-aminobutanoyl-L-leucyl-5-amino-5-deoxy-L-  
galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 435342-33-9 HCAPLUS

CN .beta.-Alanine, L-norvalyl-L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-,  
, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 435342-34-0 HCPLUS

CN .beta.-Alanine, L-norleucyl-L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 435342-35-1 HCPLUS

CN .beta.-Alanine, N-[(2S)-2-hydroxy-3-methyl-1-oxobutyl]-L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 435342-36-2 HCPLUS

CN .beta.-Alanine, N-[(1-methylhydrazino)carbonyl]-L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 435342-37-3 HCAPLUS

CN .beta.-Alanine, D-leucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 435342-38-4 HCAPLUS

CN L-Galactonamide, 5-[(4-amino-1-oxobutyl)amino]-N-[(1S)-2-carboxy-1-phenylethyl]-5-deoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 435342-40-8 HCAPLUS

CN .beta.-Alanine, L-glutaminyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 435342-41-9 HCPLUS

CN .beta.-Alanine, L-ornithyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 435342-42-0 HCPLUS

CN .beta.-Alanine, L-.alpha.-glutamyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-  
, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 435342-43-1 HCPLUS

CN Benzenepropanoic acid, .beta.-[[5-[(2S)-2-amino-1-oxobutyl]amino]-5-deoxy-  
L-galactonoyl]amino]-, (.beta.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 435342-44-2 HCPLUS

CN .beta.-Alanine, L-norleucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 435342-45-3 HCPLUS

CN .beta.-Alanine, (3E)-3,4-didehydro-L-norvalyl-5-amino-5-deoxy-L-  
galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).


Double bond geometry as shown.



RN 435342-46-4 HCPLUS

CN .beta.-Alanine, 4,5-didehydro-L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-  
phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 435342-47-5 HCPLUS

CN .beta.-Alanine, 4,4,5,5-tetrahydro-L-norvalyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L5 ANSWER 3 OF 7 HCPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:203157 HCPLUS

DOCUMENT NUMBER: 136:402014

TITLE: Total synthesis of novel antibiotics pyloricidin A, B and C and their application in the study of pyloricidin derivatives

AUTHOR(S): Hasuoka, Atsushi; Nishikimi, Yuji; Nakayama, Yutaka; Kamiyama, Keiji; Nakao, Masafumi; Miyagawa, Ken-Ichiro; Nishimura, Osamu; Fujino, Masahiko

CORPORATE SOURCE: Medicinal Chemistry Research Laboratories I, Pharmaceutical Research Division, Takeda Chemical Industries, Ltd., Osaka, 532-8686, Japan

SOURCE: Journal of Antibiotics (2002), 55(2), 191-203

CODEN: JANTAU; ISSN: 0021-8820

PUBLISHER: Japan Antibiotics Research Association

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The novel natural antibiotics pyloricidin A, B and C, which possess potent and highly selective anti-Helicobacter pylori activity, were synthesized from D-galactosamine as a chiral template for the common (2S,3R,4R,5S)-5-amino-2,3,4,6-tetrahydroxyhexanoic acid moiety. The synthetic strategy, using 2-amino-2-deoxyuronic acid derivs. as key intermediates, was also useful to prep. a series of derivs. modified at the .beta.-D-phenylalanine and with altered stereochem. on the 5-amino-2,3,4,6-tetrahydroxyhexanoic acid moiety. From the drastic decrease of their anti-H. pylori activity, it was clear that the

.beta.-D-phenylalanine part and the stereochem. of the 5-amino-2,3,4,6-tetrahydroxyhexanoic acid moiety were significant for the activity.

IT 219813-79-3P 219823-30-0P 430474-84-3P


430475-07-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
(total synthesis of antibiotics pyloricidin A, B and C and their derivs. and structure-antibacterial activity relationship of aminotetrahydroxyhexanoic acid moiety)

RN 219813-79-3 HCPLUS

CN .beta.-Alanine, L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-(4-methylphenyl)-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 219823-30-0 HCPLUS

CN .beta.-Alanine, L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 430474-84-3 HCPLUS

CN .beta.-Alanine, L-leucyl-5-amino-5-deoxy-L-gulonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 430475-07-3 HCPLUS

CN .beta.-Alanine, L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3R)-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




IT 219823-28-6P 219823-29-7P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(total synthesis of antibiotics pyloricidin A, B and C and their  
derivs. and structure-antibacterial activity relationship of  
aminotetrahydroxyhexanoic acid moiety)

RN 219823-28-6 HCPLUS

CN .beta.-Alanine, L-valyl-L-valyl-L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-  
phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 219823-29-7 HCPLUS

CN .beta.-Alanine, L-valyl-L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-,  
(3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 7 HCPLUS COPYRIGHT 2003 ACS  
 ACCESSION NUMBER: 2001:887897 HCPLUS  
 DOCUMENT NUMBER: 136:213275  
 TITLE: Pyloricidins, novel anti-Helicobacter pylori antibiotics produced by Bacillus sp. II. Isolation and structure elucidation  
 AUTHOR(S): Nagano, Yoichi; Ikeda, Koji; Fujishima, Akira; Izawa, Motowo; Tsubotani, Shigetoshi; Nishimura, Osamu; Fujino, Masahiko  
 CORPORATE SOURCE: Pharmaceutical Discovery Center, Pharmaceutical Research Division, Takeda Chemical Industries, Ltd., Osaka, 532-8686, Japan  
 SOURCE: Journal of Antibiotics (2001), 54(11), 934-947  
 CODEN: JANTAI; ISSN: 0021-8820  
 PUBLISHER: Japan Antibiotics Research Association  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English

AB Novel anti-Helicobacter pylori antibiotics, pyloricidins A, A1, A2, B, C and D were isolated from Bacillus sp. HC-70 and Bacillus sp. HC-72 by column chromatogs. using adsorption and ion exchange resins. Their structures have been elucidated based on spectroscopic and degrdn. studies and shown to be peptide-like compds. These compds. contained two unusual amino acids, viz., 5-amino-2,3,4,6-tetrahydroxyhexanoic acid and 3-amino-3-phenylpropionic acid (.beta.-phenylalanine). The structure-activity relationship studies suggested that 3-(5-amino-2,3,4,6-tetrahydroxyhexanoyl)amino-3-phenylpropionic acid moiety was essential for anti-H. pylori activity.

IT 219812-79-0P, Pyloricidin D 219823-28-6P, Pyloricidin A  
 219823-29-7P, Pyloricidin B 219823-30-0P, Pyloricidin C  
 219823-32-2P, Pyloricidin A1 219823-33-3P, Pyloricidin A2


RL: BSU (Biological study, unclassified); PRP (Properties); PUR (Purification or recovery); BIOL (Biological study); PREP (Preparation) (pyloricidins as novel anti-Helicobacter pylori antibiotics produced by Bacillus)

RN 219812-79-0 HCPLUS

CN Benzenepropanoic acid, .beta.-[(5-amino-5-deoxy-L-galactonoyl)amino]-,

(.beta.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 219823-28-6 HCPLUS

CN .beta.-Alanine, L-valyl-L-valyl-L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 219823-29-7 HCPLUS

CN .beta.-Alanine, L-valyl-L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 219823-30-0 HCPLUS

CN .beta.-Alanine, L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 219823-32-2 HCAPLUS

CN .beta.-Alanine, L-valyl-L-isoleucyl-L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 219823-33-3 HCAPLUS

CN .beta.-Alanine, L-valyl-L-leucyl-L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



REFERENCE COUNT:

16

THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 5 OF 7 HCAPLUS COPYRIGHT 2003 ACS  
ACCESSION NUMBER: 2001:887896 HCAPLUS


DOCUMENT NUMBER: 136:147569  
 TITLE: Pyloricidins, novel anti-Helicobacter pylori antibiotics produced by *Bacillus* sp. I. Taxonomy, fermentation, and biological activity  
 AUTHOR(S): Nakao, Masafumi; Miyagawa, Ken-Ichiro; Nakano, Yoshitaka; Sakane, Takeshi; Tada, Mayumi; Nishimura, Osamu; Fujino, Masahiko  
 CORPORATE SOURCE: Pharmacology Research laboratories II, Pharmaceutical Research Division, Takeda Chemical Industries, Ltd., Osaka, 532-8686, Japan  
 SOURCE: Journal of Antibiotics (2001), 54(11), 926-933  
 CODEN: JANTAJ; ISSN: 0021-8820  
 PUBLISHER: Japan Antibiotics Research Association  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English

**AB** Novel anti-Helicobacter pylori antibiotics, pyloricidins A, A1, A2, B, C, and D, were discovered in the culture broth of 2 bacilli strains. Pyloricidins selectively inhibited the growth of *H. pylori*. Pyloricidin B was efficacious in the treatment of gastric infection caused by *H. pylori* in Mongolian gerbils and may be promising for cure of *H. pylori* infection as a single agent.

**IT** 219812-79-0P, Pyloricidin D 219823-28-6P, Pyloricidin A 219823-29-7P, Pyloricidin B 219823-30-0P, Pyloricidin C 219823-32-2P, Pyloricidin A1 219823-33-3P, Pyloricidin A2  
 RL: BSU (Biological study, unclassified); NPO (Natural product occurrence); PRP (Properties); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation); USES (Uses)  
 (anti-Helicobacter pylori antibiotics, pyloricidins A, A1, A2, B, C, and D, produced by *Bacillus*)


**RN** 219812-79-0 HCPLUS  
**CN** Benzenepropanoic acid, .beta.-[(5-amino-5-deoxy-L-galactonoyl)amino]-, (.beta.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



**RN** 219823-28-6 HCPLUS  
**CN** .beta.-Alanine, L-valyl-L-valyl-L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 219823-29-7 HCAPLUS

CN .beta.-Alanine, L-valyl-L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-,  
(3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 219823-30-0 HCAPLUS

CN .beta.-Alanine, L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 219823-32-2 HCAPLUS

CN .beta.-Alanine, L-valyl-L-isoleucyl-L-leucyl-5-amino-5-deoxy-L-galactonoyl-  
3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 219823-33-3 HCPLUS

CN .beta.-Alanine, L-valyl-L-leucyl-L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 6 OF 7 HCPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2000:475680 HCPLUS

DOCUMENT NUMBER: 133:105346

TITLE: Preparation of polyol-amino acid compounds having activity against Helicobacter pylori

INVENTOR(S): Kamiyama, Keiji; Nishikimi, Yuji; Hasuoka, Atsushi; Nakao, Masafumi; Miyagawa, Ken-ichiro; Akiyama, Yohko

PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan

SOURCE: PCT Int. Appl., 91 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000040599	A1	20000713	WO 2000-JP23	20000106
W: AE, AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CR, CU, CZ, DM, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR,				

LT, LV, MA, MD, MG, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK,  
 SL, TJ, TM, TR, TT, TZ, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG,  
 KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,  
 DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,  
 CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

JP 2000256395 A2 20000919 JP 2000-5735 20000106


EP 1140979 A1 20011010 EP 2000-900126 20000106

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO

PRIORITY APPLN. INFO.: JP 1999-1898 A 19990107  
 WO 2000-JP23 W 20000106

OTHER SOURCE(S): MARPAT 133:105346

GI



AB Title compds. I (X = L-serine, L-asparagine, or (S)-2-aminobutyric acid residue; Y is .alpha.-L-amino acid residue) or their salts or prodrugs having activity against Helicobacter bacteria were prep'd. Thus, (S)-3-[(2S,3R,4R,5S)-5-[(L-norvalyl-(S)-2-aminobutyryl)amino]-2,3,4,6-tetrahydroxyhexanoyl]amino]-3-phenylpropionic acid, prep'd. from a leucine-polyol isolated from Bacillus sp. HC-72, showed min. inhibitory concn. 0.025 mg/mL against Helicobacter pylori. Pharmaceutical formulations of the above product are given.


IT 282549-81-9P 282549-83-1P

RL: BAC (Biological activity or effector, except adverse); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of polyol-amino acid compds. having activity against Helicobacter pylori)

RN 282549-81-9 HCPLUS

CN .beta.-Alanine, L-norvalyl-(2S)-2-aminobutanoyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 282549-83-1 HCPLUS

CN .beta.-Alanine, L-isoleucyl-(2S)-2-aminobutanoyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 282549-69-3P 282549-71-7P 282549-73-9P

282549-75-1P 282549-77-3P 282549-79-5P

282549-85-3P 282549-87-5P 282549-89-7P

282549-91-1P 282549-93-3P 282549-95-5P

282549-98-8P 282550-00-9P 282550-02-1P

282550-04-3P 282550-06-5P 282550-21-4P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prep. of polyol-amino acid compds. having activity against Helicobacter pylori)

RN 282549-69-3 HCPLUS

CN .beta.-Alanine, L-norvalyl-L-seryl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 282549-71-7 HCPLUS

CN .beta.-Alanine, L-isoleucyl-L-seryl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 282549-73-9 HCPLUS

CN .beta.-Alanine, L-methionyl-L-seryl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 282549-75-1 HCPLUS

CN .beta.-Alanine, L-norvalyl-L-asparaginyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 282549-77-3 HCPLUS

CN .beta.-Alanine, L-isoleucyl-L-asparaginyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 282549-79-5 HCPLUS

CN .beta.-Alanine, L-methionyl-L-asparaginyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 282549-85-3 HCPLUS

CN .beta.-Alanine, L-methionyl-(2S)-2-aminobutanoyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 282549-87-5 HCPLUS

CN .beta.-Alanine, L-asparaginyl-L-seryl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 282549-89-7 HCAPLUS

CN .beta.-Alanine, 4,5-didehydro-L-norvalyl-L-seryl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 282549-91-1 HCAPLUS

CN .beta.-Alanine, S-methyl-L-cysteinyl-L-seryl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 282549-93-3 HCAPLUS

CN .beta.-Alanine, L-asparaginyl-L-asparaginyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 282549-95-5 HCPLUS

CN .beta.-Alanine, 4,5-didehydro-L-norvalyl-L-asparaginyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 282549-98-8 HCPLUS

CN .beta.-Alanine, L-asparaginyl-(2S)-2-aminobutanoyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 282550-00-9 HCPLUS

CN .beta.-Alanine, 4,5-didehydro-L-norvalyl-(2S)-2-aminobutanoyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 282550-02-1 HCAPLUS

CN .beta.-Alanine, S-methyl-L-cysteinyll-(2S)-2-aminobutanoyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 282550-04-3 HCAPLUS

CN .beta.-Alanine, L-lysyl-(2S)-2-aminobutanoyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 282550-06-5 HCAPLUS

CN .beta.-Alanine, L-valyl-(2S)-2-aminobutanoyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 282550-21-4 HCPLUS

CN .beta.-Alanine, S-methyl-L-cysteinyll-L-asparaginyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 219823-29-7P


RL: BPN (Biosynthetic preparation); BIOL (Biological study); PREP (Preparation)

(prepn. of polyol-amino acid compds. having activity against Helicobacter pylori)

RN 219823-29-7 HCPLUS

CN .beta.-Alanine, L-valyl-L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 219823-30-0P


RL: BPN (Biosynthetic preparation); RCT (Reactant); BIOL (Biological

study); PREP (Preparation); RACT (Reactant or reagent)  
 (prepn. of polyol-amino acid compds. having activity against  
*Helicobacter pylori*)

RN 219823-30-0 HCPLUS

CN .beta.-Alanine, L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)-  
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 219812-79-0P

RL: BPN (Biosynthetic preparation); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)  
 (prepn. of polyol-amino acid compds. having activity against *Helicobacter pylori*)

RN 219812-79-0 HCPLUS

CN Benzenepropanoic acid, .beta.-[(5-amino-5-deoxy-L-galactonoyl)amino]-,  
 (.beta.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 219813-07-7P 282549-74-0P 282550-07-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (prepn. of polyol-amino acid compds. having activity against *Helicobacter pylori*)

RN 219813-07-7 HCPLUS

CN Benzenepropanoic acid, .beta.-[[5-[(2S)-2-amino-1-oxobutyl]amino]-5-deoxy-L-galactonoyl]amino]-, monohydrochloride, (.beta.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




● HCl

RN 282549-74-0 HCPLUS

CN .beta.-Alanine, N-[ (phenylmethoxy) carbonyl]-L-norvalyl-L-asparaginyl-5-  
amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 282550-07-6 HCPLUS

CN .beta.-Alanine, N-[ (phenylmethoxy) carbonyl]-L-norvalyl-(2S)-2-  
aminobutanoyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA  
INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:



4

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 7 OF 7 HCAPLUS COPYRIGHT 2003 ACS  
 ACCESSION NUMBER: 1999:64823 HCAPLUS  
 DOCUMENT NUMBER: 130:125408  
 TITLE: Preparation of polyol-amino acid compounds having activity against Helicobacter pylori  
 INVENTOR(S): Miyagawa, Ken-ichiro; Tsubotani, Shigetoshi; Nakao, Masafumi; Nakano, Yoshitaka; Kamiyama, Keiji; Izawa, Motoo; Akiyama, Yohko; Nishikimi, Yuji  
 PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan  
 SOURCE: PCT Int. Appl., 178 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9902549	A1	19990121	WO 1998-JP3066	19980708
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HR, HU, ID, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9881273	A1	19990208	AU 1998-81273	19980708
JP 11080109	A2	19990326	JP 1998-193489	19980708
EP 998488	A1	20000510	EP 1998-931013	19980708
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
ZA 9806079	A	20000110	ZA 1998-6079	19980709
TW-479054	B	20020311	TW 1998-87111146	19980709
US 6423869	B1	20020723	US 1999-423118	19991101
PRIORITY APPLN. INFO.:			JP 1997-184086	A 19970709
			WO 1998-JP3066	W 19980708

OTHER SOURCE(S): MARPAT 130:125408  
 GI



AB Title compds. I [R1 = (un)substituted amino, (un)substituted amino acid residue, (un)substituted peptide residue; R2 = optionally esterified or amidated carboxy; R3, R4, R5, R6 independently = (un)protected OH; Q = (un)substituted aryl] or a salt thereof, isolated from *Bacillus* cultures and chem. modified, are described. I possess anti-*Helicobacter pylori* activity, and useful in the prevention or treatment of various diseases assocd. with *Helicobacter* bacteria, such as duodenal ulcer, gastric ulcer, chronic gastritis, and cancer of the stomach. Thus, leucine-polyol conjugate II (R = H, R7 = OH) (HC-70III), isolated from *Bacillus* sp. HC-70 or from *Bacillus insolitus* HC-72, underwent N-terminal peptide coupling with a variety of amino acid derivs., or amidation or esterification at the C-terminus to give a variety of derivs., e.g. II [R = H, PhCH<sub>2</sub>O<sub>2</sub>C (Cbz), H-Ala, H-Sar, H-Phe, H-Lys, H-Glu, H-Orn, H-Asn, H-Gln, H-Thr, H-Leu, H-Ile, H-Ser(Me), H-Val, H-Nva, H-Nle, H-D-Ala, R7 = OH, OCHPh<sub>2</sub>, OEt, OCH<sub>2</sub>OCHMe<sub>3</sub>, NH<sub>2</sub>]. A variety of pharmaceutical formulations contg. I (R = H, R7 = OH) are given.

IT 219812-79-0P 219823-29-7P, HC 70II 219823-30-0P


, HC 70III


RL: BAC (Biological activity or effector, except adverse); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (fermentative prepn. and chem. modification of polyol-amino acid compds. having activity against *Helicobacter pylori*)

RN 219812-79-0 HCPLUS

CN Benzenepropanoic acid, .beta.-[(5-amino-5-deoxy-L-galactonoyl)amino]-, (.beta.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 219823-29-7 HCPLUS

CN .beta.-Alanine, L-valyl-L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-,  
(3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 219823-30-0 HCPLUS

CN .beta.-Alanine, L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 219823-28-6P, HC 70I 219823-32-2P, HC 70IA


219823-33-3P, HC 70IB

RL: BAC (Biological activity or effector, except adverse); BPN  
(Biosynthetic preparation); BSU (Biological study, unclassified); THU  
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
(Uses)(fermentative prepn. and chem. modification of polyol-amino acid  
compds. having activity against Helicobacter pylori)

RN 219823-28-6 HCPLUS

CN .beta.-Alanine, L-valyl-L-valyl-L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-  
phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 219823-32-2 HCAPLUS

CN .beta.-Alanine, L-valyl-L-isoleucyl-L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 219823-33-3 HCAPLUS

CN .beta.-Alanine, L-valyl-L-leucyl-L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT 219812-83-6P 219812-88-1P 219813-22-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological


study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(fermentative prepn. and chem. modification of polyol-amino acid compds. having activity against Helicobacter pylori)

RN 219812-83-6 HCPLUS

CN .beta.-Alanine, L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, monohydrochloride, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 219812-88-1 HCPLUS

CN .beta.-Alanine, N-[ (phenylmethoxy) carbonyl]-L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 219813-22-6 HCPLUS


CN Benzenepropanoic acid, .beta.-[[5-[(2S)-2-amino-1-oxo-4-pentenyl]amino]-5-deoxy-L-galactonoyl]amino]-, (.beta.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



- IT 219812-80-3P 219812-95-0P 219812-96-1P  
 219812-97-2P 219812-98-3P 219813-01-1P  
 219813-02-2P 219813-04-4P 219813-05-5P  
 219813-06-6P 219813-07-7P 219813-08-8P  
 219813-09-9P 219813-10-2P 219813-12-4P  
 219813-13-5P 219813-14-6P 219813-15-7P  
 219813-16-8P 219813-18-0P 219813-19-1P  
 219813-20-4P 219813-21-5P 219813-23-7P  
 219813-24-8P 219813-25-9P 219813-26-0P  
 219813-28-2P 219813-29-3P 219813-30-6P  
 219813-31-7P 219813-32-8P 219813-33-9P  
 219813-34-0P 219813-35-1P 219813-36-2P  
 219813-37-3P 219813-38-4P 219813-39-5P  
 219813-41-9P 219813-42-0P 219813-43-1P  
 219813-44-2P 219813-45-3P 219813-46-4P  
 219813-47-5P 219813-48-6P 219813-51-1P  
 219813-53-3P 219813-55-5P 219813-57-7P  
 219813-58-8P 219813-65-7P 219813-66-8P  
 219813-67-9P 219813-68-0P 219813-69-1P  
 219813-70-4P 219813-71-5P 219813-73-7P  
 219813-74-8P 219813-75-9P 219813-76-0P  
 219813-77-1P 219813-79-3P 219823-31-1P, HC  
 70II monohydrochloride  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (fermentative prepn. and chem. modification of polyol-amino acid compds. having activity against Helicobacter pylori)  
 RN 219812-80-3 HCPLUS  
 CN .beta.-Alanine, N-acetyl-L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, monosodium salt, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Na

RN 219812-95-0 HCPLUS

CN .beta.-Alanine, L-ornithyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-,  
dihydrochloride, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




● 2 HCl

RN 219812-96-1 HCPLUS

CN .beta.-Alanine, L-.alpha.-glutamyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-,  
monohydrochloride, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




● HCl

RN 219812-97-2 HCPLUS

CN .beta.-Alanine, O-methyl-L-seryl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-,  
(3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 219812-98-3 HCPLUS

CN .beta.-Alanine, O-(phenylmethyl)-L-seryl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 219813-01-1 HCPLUS

CN .beta.-Alanine, L-seryl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 219813-02-2 HCAPLUS

CN .beta.-Alanine, L-isoleucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 219813-04-4 HCAPLUS

CN .beta.-Alanine, L-alanyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 219813-05-5 HCAPLUS


CN .beta.-Alanine, L-valyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 219813-06-6 HCPLUS  
 CN .beta.-Alanine, L-norvalyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)-  
 (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 219813-07-7 HCPLUS  
 CN Benzenepropanoic acid, .beta.-[[5-[(2S)-2-amino-1-oxobutyl]amino]-5-deoxy-  
 L-galactonoyl]amino]-, monohydrochloride, (.beta.S)- (9CI) (CA INDEX  
 NAME)


Absolute stereochemistry. Rotation (-).



● HCl

RN 219813-08-8 HCPLUS  
 CN .beta.-Alanine, L-phenylalanyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-,  
 (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 219813-09-9 HCPLUS

CN .beta.-Alanine, 3-(acetylamino)-L-alanyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 219813-10-2 HCPLUS

CN .beta.-Alanine, L-prolyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 219813-12-4 HCPLUS

CN .beta.-Alanine, 5,5,5-trifluoro-L-norvalyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 219813-13-5 HCAPLUS

CN Benzenepropanoic acid, .beta.-[(5-[(2S)-2-amino-4,4,4-trifluoro-1-oxobutyl]amino]-5-deoxy-L-galactonoyl]amino]-, (.beta.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 219813-14-6 HCAPLUS

CN .beta.-Alanine, 3-[(methylsulfonyl)amino]-L-alanyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 219813-15-7 HCAPLUS

CN .beta.-Alanine, 5-fluoro-L-norvalyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 219813-16-8 HCPLUS

CN .beta.-Alanine, 3-(formylamino)-L-alanyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 219813-18-0 HCPLUS

CN .beta.-Alanine, L-homoseryl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 219813-19-1 HCPLUS

CN .beta.-Alanine, 3-cyano-L-alanyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 219813-20-4 HCPLUS

CN .beta.-Alanine, L-methionyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 219813-21-5 HCPLUS

CN .beta.-Alanine, S-methyl-L-cysteinyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 219813-23-7 HCPLUS

CN .beta.-Alanine, L-alanyl-L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-,  
(3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 219813-24-8 HCPLUS

CN .beta.-Alanine, N-methylglycyl-L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 219813-25-9 HCPLUS

CN .beta.-Alanine, L-phenylalanyl-L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 219813-26-0 HCPLUS

CN .beta.-Alanine, L-lysyl-L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, dihydrochloride, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




●2 HCl

RN 219813-28-2 HCPLUS

CN .beta.-Alanine, L-.alpha.-glutamyl-L-leucyl-5-amino-5-deoxy-L-galactonoyl-  
3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 219813-29-3 HCPLUS

CN .beta.-Alanine, N-(4-amino-1-oxobutyl)-L-leucyl-5-amino-5-deoxy-L-  
galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 219813-30-6 HCPLUS

CN .beta.-Alanine, L-ornithyl-L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-  
, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 219813-31-7 HCAPLUS

CN .beta.-Alanine, L-asparaginyl-L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 219813-32-8 HCAPLUS

CN .beta.-Alanine, L-glutaminyl-L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 219813-33-9 HCAPLUS

CN .beta.-Alanine, 3-(acetylamino)-L-alanyl-L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 219813-34-0 HCPLUS

CN .beta.-Alanine, 3-amino-L-alanyl-L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 219813-35-1 HCPLUS

CN .beta.-Alanine, O-methyl-L-threonyl-L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 219813-36-2 HCPLUS

CN .beta.-Alanine, 3-cyclohexyl-L-alanyl-L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 219813-37-3 HCPLUS

CN .beta.-Alanine, 5,5,5-trifluoro-L-norvalyl-L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 219813-38-4 HCPLUS

CN .beta.-Alanine, L-leucyl-L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 219813-39-5 HCPLUS

CN .beta.-Alanine, L-isoleucyl-L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 219813-41-9 HCPLUS

CN .beta.-Alanine, O-methyl-L-seryl-L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 219813-42-0 HCPLUS

CN .beta.-Alanine, 2-phenylglycyl-L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 219813-43-1 HCPLUS

CN .beta.-Alanine, N-methyl-L-valyl-L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 219813-44-2 HCPLUS

CN .beta.-Alanine, (2S)-2-aminobutanoyl-L-leucyl-5-amino-5-deoxy-L-  
galactonoyl-3-phenyl-, monohydrochloride, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




● HCl

RN 219813-45-3 HCPLUS

CN .beta.-Alanine, L-norvalyl-L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-  
, monohydrochloride, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




● HCl

RN 219813-46-4 HCPLUS

CN .beta.-Alanine, L-norleucyl-L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, monohydrochloride, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




● HCl

RN 219813-47-5 HCPLUS

CN .beta.-Alanine, D-alanyl-L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, monohydrochloride, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




● HCl

RN 219813-48-6 HCPLUS

CN .beta.-Alanine, 3-cyano-L-alanyl-L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 219813-51-1 HCAPLUS

CN .beta.-Alanine, L-.alpha.-aspartyl-L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, 1-methyl ester, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 219813-53-3 HCAPLUS

CN .beta.-Alanine, glycyl-L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 219813-55-5 HCAPLUS

CN .beta.-Alanine, L-prolyl-L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 219813-57-7 HCAPLUS

CN .beta.-Alanine, O-(phenylmethyl)-L-seryl-L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 219813-58-8 HCAPLUS

CN .beta.-Alanine, L-seryl-L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 219813-65-7 HCAPLUS

CN .beta.-Alanine, L-tryptophyl-L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 219813-66-8 HCAPLUS

CN .beta.-Alanine, 2-methylalanyl-L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 219813-67-9 HCAPLUS

CN .beta.-Alanine, N-[(1-aminocyclohexyl)carbonyl]-L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 219813-68-0 HCAPLUS

CN .beta.-Alanine, L-methionyl-L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 219813-69-1 HCPLUS

CN .beta.-Alanine, S-methyl-L-cysteinyl-L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 219813-70-4 HCPLUS

CN .beta.-Alanine, 4,5-didehydro-L-norvalyl-L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 219813-71-5 HCPLUS

CN .beta.-Alanine, 5-oxo-L-prolyl-L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 219813-73-7 HCAPLUS

CN .beta.-Alanine, L-valyl-N-methyl-L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 219813-74-8 HCAPLUS

CN .beta.-Alanine, N-[ (2S)-2-amino-3-methylbutyl]-L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 219813-75-9 HCAPLUS

CN .beta.-Alanine, L-norvalyl-4,5-didehydro-L-norvalyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 219813-76-0 HCAPLUS

CN .beta.-Alanine, L-isoleucyl-4,5-didehydro-L-norvalyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 219813-77-1 HCAPLUS

CN .beta.-Alanine, L-methionyl-4,5-didehydro-L-norvalyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 219813-79-3 HCAPLUS

CN .beta.-Alanine, L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-(4-methylphenyl)-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 219823-31-1 HCPLUS

CN .beta.-Alanine, L-valyl-L-leucyl-5-amino-5-deoxy-L-galactonoxy-3-phenyl-,  
monohydrochloride, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

REFERENCE COUNT:

3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

93212

Access DB# \_\_\_\_\_

**SEARCH REQUEST FORM****Scientific and Technical Information Center**

Requester's Full Name: Mike Miller Examiner #: 69404 Date: 5/5/03  
 Art Unit: 1654 Phone Number 30374230 Serial Number: 09/757,887  
 Mail Box and Bldg/Room Location: C111 Results Format Preferred (circle):  PAPER  DISK  E-MAIL  
TO A03

If more than one search is submitted, please prioritize searches in order of need.

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: Poly compounds, their production & use

Inventors (please provide full names): Kenji Yamizawa, Yuji Nishikuni, Atsushi  
Ishii, Masafumi Nakao, Ken-ichiro Miyagawa, Yohko Akiyama

Earliest Priority Filing Date: 1/7/1999

\*For Sequence Searches Only\* Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.

Please Search Compound of  
Claim 1.

POINT OF CONTACT:  
PAUL SCHULWITZ  
TECHNICAL INFO. SPECIALIST  
CM1 6B06 TEL. (703) 305-1954

<b>STAFF USE ONLY</b>	<b>Type of Search</b>	<b>Vendors and cost where applicable</b>
Searcher: _____	NA Sequence (#) _____	STN <u>185.17</u>
Searcher Phone #: _____	AA Sequence (#) _____	Dialog _____
Searcher Location: _____	Structure (#) <u>1</u>	Questel/Orbit _____
Date Searcher Picked Up: <u>5/5</u>	Bibliographic _____	Dr.Link _____
Date Completed: <u>5/5</u>	Litigation _____	Lexis/Nexis _____
Searcher Prep & Review Time: <u>10</u>	Fulltext _____	Sequence Systems _____
Clerical Prep Time: _____	Patent Family _____	WWW/Internet _____
Online Time: <u>7</u>	Other _____	Other (specify) _____

Keiji KAMIYAMA et al.

Attn: BOX PCT

8-22-01  
57

Serial No. NEW

Docket No. 2001\_0710A

Filed June 13, 2001

POLYOL COMPOUNDS, THEIR PRODUCTION AND USE  
[Corresponding to PCT/JP00/00023  
Filed January 6, 2000]

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents,  
Washington, DC 20231

Sir:

Prior to calculating the filing fee, please amend the above-identified application as follows:

IN THE SPECIFICATION


*Page 1, immediately after the title, please insert:*

This application is a 371 of PCT/JP00/00023 filed January 6, 2000.

IN THE CLAIMS

*Please amend the claims as follows:*

I. 1. (Amended) A compound of the formula:



Sp. (1)

continued on  
next page →

ATTACHMENT E

wherein X is L-serine residue, L-asparagine residue or (S)-2-aminobutyric acid residue and Y is  $\alpha$ -L-amino acid residue, or a salt thereof.

7. (Amended) A pharmaceutical composition which comprises the compound claimed in claim 1 or its pro-drug and a pharmaceutically acceptable additive.


12. (Amended) A pharmaceutical composition which is a gastric mucosa adhesive pharmaceutical composition comprising (a) a compound as claimed in claim 1, (b) a lipid and/or a polyglycerol fatty acid ester and (c) a viscoelastic agent capable of being viscous with water

19. (Amended) A method for manufacturing a pharmaceutical composition for *Helicobacter pylori* infectious disease, which comprises mixing the compound according to claim 1 or its pro-drug with a pharmaceutically acceptable additive.

20. (Amended) The method as claimed in claim 19, wherein the composition is for treating or preventing a *Helicobacter pylori* infectious disease.

21. (Amended) The method as claimed in claim 20, wherein the *Helicobacter pylori* infectious disease is gastric or duodenal ulcer, gastritis, gastric cancer or gastric MALT lymphoma.

22. (Amended) A method for producing a compound claimed in claim 1, which comprises reacting a compound of the formula:



(11)